Immutep reports positive data in head and neck cancer trial
Immutep (ASX:IMM) has announced promising new data from its Phase IIb TACTI-003 trial, presented at the ESMO Immuno-Oncology Congress 2024. The trial combines the company’s lead drug candidate eftilagimod alpha (efti) with Merck & Co’s drug KEYTRUDA (pembrolizumab). The targeted indication is head and neck squamous cell carcinoma (HNSCC). Cancer cells hiding from T-cells T-cells […]
Immutep reports positive data in head and neck cancer trial Read More »
								








